基础医学与临床 ›› 2023, Vol. 43 ›› Issue (6): 948-952.doi: 10.16352/j.issn.1001-6325.2023.06.0948

• 研究论文 • 上一篇    下一篇

LncRNA CBR3-AS1在多发性骨髓瘤中的表达及临床意义

张永梅*, 张志敏, 周洁, 潘志兰, 冯丽倩, 杨彦   

  1. 石家庄市人民医院 血液内科,河北 石家庄 050000
  • 收稿日期:2021-11-26 修回日期:2022-04-12 出版日期:2023-06-05 发布日期:2023-05-31
  • 通讯作者: *zhangyongmei1986z@163.com
  • 基金资助:
    河北省卫生健康委员会资助项目(20210067,20160803)

Expression and clinical significance of LncRNA CBR3-AS1 in multiple myeloma

ZHANG Yongmei*, ZHANG Zhiming, ZHOU Jie, PAN Zhilan, FENG Liqian, YANG Yan   

  1. Department of Hematology, Shijiazhuang People's Hospital,Shijiazhuang 050000, China
  • Received:2021-11-26 Revised:2022-04-12 Online:2023-06-05 Published:2023-05-31
  • Contact: *zhangyongmei1986z@163.com

摘要: 目的 检测多发性骨髓瘤患者血清中长链非编码羰基还原酶3反义RNA1(LncRNA CBR3-AS1)的表达水平,并分析其临床意义。方法 该研究纳入石家庄市人民医院2012年1月至2020年3月期间初诊的100例多发性骨髓瘤患者作为观察组,另纳入50名65岁以下的健康体检人员作为对照组。用RT-qPCR技术检测LncRNA CBR3-AS1在血清中的相对表达,分析血清LncRNA CBR3-AS1的表达水平与多发性骨髓瘤患者临床参数的关系;Kaplan-Meier(K-M)法生存曲线分析血清LncRNA CBR3-AS1表达水平与多发性骨髓瘤患者预后的关系;单因素、多因素Cox回归评估可能影响多发性骨髓瘤患者预后的因素。结果 观察组血清中LncRNA CBR3-AS1的相对表达水平显著高于对照组(P<0.05);多发性骨髓瘤患者血清中LncRNA CBR3-AS1的相对表达水平与临床传统分期系统(D-S)分期、国际分期系统(ISS)分期有关(P<0.05);LncRNA CBR3-AS1低表达组患者的生存率(78.0%)明显高于LncRNACBR3-AS1高表达组的患者(58.0%)(χ2=5.370,P<0.05);单因素分析结果显示,临床D-S分期(HR=2.159;95% CI=1.323~3.524;P<0.05)和ISS分期(HR=1.746;95% CI=1.091~2.794;P<0.05)及血清LncRNA CBR3-AS1的表达(HR=1.975;95% CI=1.210~3.224;P<0.05)影响多发性骨髓瘤患者的预后,多因素COX回归分析结果表明临床D-S分期(HR=2.769;95% CI=1.315~5.832;P<0.05)、ISS分期(HR=2.495;95% CI=1.117~5.573;P<0.05)及血清LncRNA CBR3-AS1的表达(HR=3.214;95% CI=1.206~8.564;P<0.05)均可作为多发性骨髓瘤的独立影响因素。结论 CBR3-AS1在多发性骨髓患者中高表达,并且可能与多发性骨髓瘤患者的预后有关。

关键词: 多发性骨髓瘤, 长链非编码羰基还原酶3反义RNA1, 临床参数, 预后分析

Abstract: Objective To detect the expression level of long non-coding carbonyl reductase 3 antisense RNA1(LncRNA CBR3-AS1) in the serum of patients with multiple myeloma and analyze its clinical significance. Methods This study included 100 patients with multiple myeloma who were first diagnosed in Shijiazhuang People's Hospital from January 2012 to March 2020 as the observation group, and 50 healthy people under the age of 65 who had taken physical examination as the control group. Fluorescence quantitative PCR technology was used to detect the relative expression level of LncRNA CBR3-AS1 in the serum of each group, the relationship between the expression level of serum LncRNA CBR3-AS1 and the clinical parameters of patients with multiple myeloma was analyzed and compared, Kaplan-Meier survival curve was used to analyze the relationship between the expression level of serum LncRNA CBR3-AS1 and the prognosis of patients with multiple myeloma, univariate and multivariate Cox regression were used to assess the factors that may affect the prognosis of patients with multiple myeloma. Results The relative expression level of LncRNA CBR3-AS1 in the serum of the observation group was significantly higher than that of the control group (P<0.05); The relative expression level of LncRNA CBR3-AS1 in the serum of patients with multiple myeloma was related to clinical Durie-Salmon (D-S) staging and International Staging System (ISS) staging(P<0.05); Kaplan-Meier survival curve showed that the survival rate of patients in the LncRNA CBR3-AS1 low expression group (78.0%) was significantly higher than that of the patients in the LncRNACBR3-AS1 high expression group (58.0%)(χ2=5.370, P<0.05); Univariate analysis showed that clinical D-S staging (HR=2.159; 95% CI=1.323-3.524; P<0.05), ISS staging(HR=1.746; 95% CI=1.091-2.794; P<0.05) and serum LncRNA CBR3-AS1 expression (HR=1.975; 95% CI=1.210-0.224; P<0.05) affected the prognosis of patients with multiple myeloma, multivariate Cox regression analysis showed that clinical D-S staging (HR=2.769; 95% CI=1.315-5.832; P<0.05), ISS staging (HR=2.495; 95% CI=1.117-5.573; P<0.05) and serum LncRNA CBR3-AS1 expression (HR=3.214; 95% CI=1.206-8.564; P<0.05) were potential independent influencing factors to development of multiple myeloma. Conclusions Expression of CBR3-AS1 is increased in the serum of patients with multiple myeloma, which may relate to the prognosis of multiple myeloma.

Key words: multiple myeloma, long non-coding carbonyl reductase 3 antisense RNA1(LncRNA CBR3-AS1), clinical parameters, prognostic analysis

中图分类号: